We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App

New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015

By LabMedica International staff writers
Posted on 28 Jul 2015
Print article
The PreludeLX-4MD, a four-channel HPLC that quadruples clinical throughput capabilities by performing up to 4 parallel LC-MS separations simultaneously in a single instrument.
The PreludeLX-4MD, a four-channel HPLC that quadruples clinical throughput capabilities by performing up to 4 parallel LC-MS separations simultaneously in a single instrument. (Photo courtesy of Thermo Fisher Scientific)
A new Class-I, four-channel HPLC that enables labs to increase efficiency by performing multiple parallel LC-MS separations simultaneously in a single instrument, is being exhibited at the AACC 2015 Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA) in Booth 3135.

Thermo Fisher Scientific Inc. (Waltham, MA, USA) now offers its new Prelude LX-4 MD HPLC, listed with the FDA as a Class I medical device for general clinical use. Prelude LX-4 MD HPLC quadruples the productivity of a single-channel HPLC by using four parallel channels to deliver up to 4 separations in a single instrument, streamlining LC-MS workflows, reducing mass spectrometer idle time, and keeping free valuable bench space. The four channels can run identical or different LC-MS assays simultaneously, providing flexibility for varying clinical separations and maximizing mass spectrometer utilization.

"We are strongly committed to bringing the advantages of LC-MS to the clinical market,” said Bradley Hart, Thermo Fisher Scientific, “The Prelude LX-4 MD is one of the first products within a broader initiative to make sample separations and mass spectrometry more useful and accessible to the clinician.”

Prelude LX-4 MD is the newest addition to the family of Thermo Scientific chromatography and mass spectrometry instruments and software for the clinical lab, which includes the Endura MD triple quadrupole mass spectrometer, Prelude MD HPLC, and software ClinQuan MD.

Related Links:

Thermo Fisher Scientific
Thermo Scientific Clinical Diagnostics
American Association for Clinical Chemistry (AACC)

Gold Supplier
Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
Neonatal Analyzer
CareStart S1 Analyzer
Gold Supplier
Automated Immune Analyzer
UNION Immune Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
Click here to Register



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.